medigraphic.com
Instituto Nacional de Salud Pública

2003, Number 4

<< Back Next >>

salud publica mex 2003; 45 (4)

Validation of an instrument to measure behavioral competencies in HIV+ persons

Piña-López JA

Language: Spanish
References: 56
Page: 293-297
PDF size: 89.53 Kb.


ABSTRACT

Objective. To assess the reliability and validity of an instrument to measure behavioral competences in HIV/AIDS-infected persons. Material and Methods. A cross-sectional study was conducted in November and December 2002 in Hermosillo, Sonora State, Mexico. An instrument consisting of 24 items was applied to 60 HIV-positive subjects who received health care through two Mexican Ministry of Health institutions. Statistical analysis consisted of Student s t test for item discrimination and Cronbach s alpha for testing construct reliability. Results. All but two items were able to discriminate correctly; factorial analysis resulted in three factors that jointly accounted for 48% of the variance. Finally a two-item index was obtained. The survey as a whole attained a Cronbach s alpha of 0.856. Conclusions. And advantage of this instrument is that it is clear, as it has good item discrimination.In addition, this instrument has construct validity.


REFERENCES

  1. Remor EA. Valoración de la adhesión al tratamiento antirretroviral en pacientes VIH+. Psicothema 2000;14:262-267.

  2. Remor EA, Carrobles JA. Versión española de la escala de estrés percibido (PSS-14): estudio psicométrico en una muestra VIH+. Ansiedad y Estrés 2001;7:195-201.

  3. Kalichman SC, DiFonzo K, Austin J, Luke W, Rompa D. Prospective study of emotional reactions to change in HIV viral load. AIDS Patient Care & Stds 2002;16:113-120.

  4. Remor EA. Apoyo social y calidad de vida en la infección por el VIH. Atención Primaria 2002;30:143-148.

  5. Ortiz F, Arranz P, Remor EA. Presentación de un modelo de evaluación del grado de sufrimiento percibido en una muestra de pacientes hemofílicos VIH+. Revista Electrónica de Psicología 2000; 4:1-6.

  6. Jenkins RA, Patterson TL. HIV locus of control and adaptation to seropositivity. Appli Soc Psychol 1998;2:95-98.

  7. González-Puente JA, Sánchez-Sosa JJ. Systematic assessment of quality of life in HIV-positive patients at three clinical stages of the infection. International Journal of Clinical and Health Psychology 2001;1:519-528.

  8. Ribes E, Sánchez S. El problema de las diferencias individuales: un análisis conceptual de la personalidad. En: Ribes E, Ed. Problemas conceptuales en el análisis del comportamiento humano. México, DF: Editorial Trillas, 1990.

  9. Bayés R. Variaciones sobre un modelo psicológico de prevención de enfermedad y su aplicación al caso del SIDA. Acta Comportamentalia 1992;0:33-50.

  10. Ribes E. Psicología y salud: un análisis conceptual. Barcelona: Martínez Roca, 1990.

  11. Bayés R, Ribes E. Un modelo psicológico de prevención de enfermedad: su aplicación al caso del SIDA. En: Piña JA, Comp. Psicología y salud: aportes del análisis de la conducta. Hermosillo, México: Editorial UNISON, 1992.

  12. Rodríguez ML, Moreno D, Robles S, Díaz-González E. El sida desde el modelo psicológico de salud biológica. Psicología y Salud 2000;10:161-175.

  13. Corral V. Condiciones que incrementan la precisión de los reportes verbales del comportamiento. Revista Latina de Pensamiento y Lenguaje 1999;7:107-124.

  14. Cortada de Kohan N. Importancia de la investigación psicométrica. Revista Latinoamericana de Psicología 2002;34:229-240.

  15. Piña JA, Togawa C, Coronado M, Fierros LE. Evaluación de un programa de intervención médico-psicológica dirigido a personas que viven con VIH/SIDA. Revista Chilena de Psicología 2000;21:119-129.

  16. Wagner GJ, Remien RH, Carballo-Diéguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care 2002;14:105-109.

  17. Bangsber DR, Bronstone A, Hofmann R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care 2002;14:3-15.

  18. Carrobles JA, Remor E, Rodríguez-Alzamora L. Afrontamiento, apoyo social percibido y distrés emocional en pacientes con infección por VIH. Psicothema 2003;15:420-426.

  19. Remor E, Carrobles JA, Arranz P, Martínez-Donate A, Ulla S. Ansiedad y percepción de control en la infección por VIH y SIDA. Psicología Conductual 2001;9:323-336.

  20. Vosvick M, Gore-Felton C, Koopman C, Thoresen C, Krumboltz J, Spiegel D. Maladaptative coping strategies in relation to quality of life among HIV+ adults. AIDS and Behavior 2002;6:97-106.

  21. Bayés R. Tras la 14a Conferencia Internacional sobre el SIDA, ¿cuánto sufrimiento nos espera todavía? Revista Española de Drogodependencias 2002;27:226-235.

  22. Bayés R. Infección por VIH: aspectos psicológicos. En: Bueno F, Nájera R, Eds. Salud pública y SIDA. Madrid: Ediciones Doyma; 2001.

  23. Del Río C, Franco-Paredes C. Bioterrorismo: un nuevo problema de salud pública. Salud Publica Mex 2001;43(6):585-588.

  24. O’Toole T. Smallpox: An attack scenario. Emerg Infect Dis 1999;5(4):540-551.

  25. Danzig R, Berkowsky PB. Why should we be concerned about biological warfare? JAMA 1997:278(5):431-432.

  26. Christopher GW, Cieslak TJ, Pavlin J, Eitzen EM. Biological warfare: A historical perspective. JAMA 1997:278(5):412-417.

  27. Varkey P, Poland G, Cockerill F. Confronting bioterrorism: Physicians on the front line. Mayo Clin Proceed 2002;77:661-672.

  28. Henderson DA. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 2002;34:79-83.

  29. Borio L, Inglesby T, Peters CJ. Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 2002:287(18):2391-2405.

  30. Henderson DA, Inglesby TV, Bartlett J, Ascher M, Eitzen E, Jahrling PB et al. Smallpox as a biological weapon: Medical and public health management. JAMA 1999;281(220):2127-2137.

  31. McNeill WH. Plagues and peoples. Garden City (NY): Anchor Press/Doubleday, 1976.

  32. Diamond J. Up to the starting line. Guns, Germs, Steel. The fates of human societies. New York (NY): WW Norton and Company, 1999: 35-52.

  33. Henderson DA, Moss B. Smallpox and vaccinia. En: Plotkin S, Orenstein W, ed. Vaccines. Third Edition. Filadelfia (PA): W.B. Saunders Company, 1999:74-97.

  34. Fenner F, Henderson DA, Arita I, Jezek Z, Ladvi ID. The epidemiology of smallpox. En: Fenner F, Henderson D.A. Arita I, Jezek Z, Ladvi ID, Ed. Smallpox and its eradication. Chapter 4. Ginebra: World Health Organization, 1988.

  35. Fenner F, Henderson DA, Arita I, Jezek Z, Ladvi ID. The clinical features of smallpox. En: Fenner F, Henderson D.A. Arita I, Jezek Z, Ladvi ID, Ed. Smallpox and its eradication. Chapter 1. Ginebra, World Health Organization, 1988.

  36. World Health Organization. Smallpox eradication: Temporary retention of variola virus stocks. Wkly Epidemiol Record 2001;19: 142-145.

  37. Centers for Disease Control. Strengthening national preparedness for smallpox: An update. Emerg Infect Dis 2001;7(1):155-156.

  38. Metlzer MI, Damon I, LeDuc JW, Millar JD. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001;7(6):1-19.

  39. Centers for Disease Control. Vaccinia (smallpox) vaccine. Recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR Morb Mortal Wkly Rep 2001;50:1-25.

  40. Centers for Disease Control. En: Atkinson W, Wolfe C, Ed. Epidemiology and prevention of vaccine-preventable diseases. Seventh Edition. Atlanta (GA): CDC, 2002:230-250.

  41. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972;125:161-169.

  42. Mack T. A different view of smallpox and vaccination. N Engl J Med2003;348(5):460-463.

  43. World Health Organization. WHO Advisory Committee on Variola Virus Research. Report of the Third Meeting. Ginebra, Suiza: WHO, December 2001. Disponible en: www.who.int/emc.

  44. World Health Organization. WHO Smallpox eradication: Destruction of Variola virus stocks-WHO Advisory Committee on Variola Virus Research. Report by the Secretariat of the Fourth Meeting. Ginebra, Suiza: WHO, December 2002. Disponible en: www.who.int/emc.

  45. Barquet N, Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Ann Intern Med 1997:127:635-642.

  46. Rosenthal SR, Merchlinsky M, Kleppinger C. Developing new smallpox vaccines. Emerg Infect Dis 2001;7:7.

  47. Lane JM, Rubén FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J Infect Dis 1970;122:303-309.

  48. Schraeder TL, Campion EW. Smallpox vaccination-the call to arms. N Engl J Med 2003;348(5):381-382.

  49. Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003;348(5):439-446.

  50. Bozzette S, Boer R, Bhatnagar V, Brower JL, Keeler EB, Morton SC et al. A model for a smallpox-vaccination policy. N Engl J Med 2003;348(5):416-425.

  51. Blendon RJ, DesRoches C, Benson JM, Herrmann MJ, Taylor-Clark K, Weldon KJ. The public and the smallpox threat. N Engl J Med 2003;348(5):426-432.

  52. Halloran ME, Longini IM, Nizam A, Yang Y. Containing bioterrorist smallpox. Science 2002;15:298(5597):1428-1432.

  53. Connolly C. Two Hospitals refuse call to vaccinate workers. Washington Post 2002 December 18;A2.

  54. Gettleman J. Two hospitals refuse to join Bush’s plan for smallpox. New York Times 2002 December 19;A2.

  55. Hanrahan JA, Jakubowcyz M, Davis BR. A smallpox false alarm. N Engl J Med 2003;348(5):467-468.

  56. Bartlett J, Borio L, Radonovich L, Samia Mair J, O’Toole T, Mair M et al. Smallpox vaccination in 2003: Key information for clinicians. Clin Infect Dis 2003;36:883-902.




2020     |     www.medigraphic.com